The short answer
PubMed indexes roughly 231 Semax records. The mechanistic literature appears in international journals including Brain Research and BMC Genomics and is conducted almost entirely in rats. The clinical literature is concentrated in Russian-language journals, principally the Korsakov Journal of Neurology and Psychiatry.
Key facts
- Indexed PubMed records
- ~231
- Mechanistic work
- Predominantly rat models
- International journals
- Brain Res, BMC Genomics, J Mol Neurosci
- Clinical work
- Largely Russian-language
- Principal clinical journal
- Zh Nevrol Psikhiatr Im S S Korsakova
- Earliest clinical records
- Late 1990s
- Western regulatory review
- None
Two literatures, not one
Semax's evidence base splits unusually cleanly. Mechanistic and preclinical work appears in international peer-reviewed journals and is accessible in English: the BDNF and trkB study in Brain Research, the focal-ischaemia transcriptomics in BMC Genomics, the neurotrophin dynamics work in the Journal of Molecular Neuroscience. Clinical work is concentrated in Russian-language publications, indexed on PubMed by title translation but frequently without accessible English full text.
What that means for assessment
It creates an asymmetry. A reader can evaluate the preclinical mechanistic claims directly, because the papers are available and the methods are described in a language and format they can check. The clinical claims are harder to assess independently. That is not because the work does not exist, but because language and access barriers sit between the reader and the methods. Neither dismissing it nor accepting it uncritically is defensible.
Research material referenced
Semax 10mg, third-party HPLC tested
Age of the clinical record
Records on Semax in ischaemic stroke appear from the late 1990s, with further work published subsequently. Trials from that period generally predate current standards for pre-registration, estimand specification and reporting. That is a statement about when the work was done rather than a judgement of the investigators.
Scale, in context
231 records is a modest literature. For comparison, BPC-157 and TB-500 have accumulated comparable or larger bodies of work, while a widely used approved medicine typically has thousands. Around a decade of concentrated attention plus a longer tail of Russian institutional research produces a body of evidence that is real but not deep.
How to search it
PubMed indexes the field under 'Semax'. Filtering to English-language records isolates the internationally published mechanistic work; removing that filter reveals how much of the clinical record sits outside it. Comparing the two counts is itself informative about the shape of the evidence.
Frequently asked questions
Is the Russian clinical literature legitimate?
It is peer-reviewed and PubMed-indexed. The difficulty is access and independent assessment, not existence. Treat it as evidence that is hard to verify rather than as evidence that is absent.
Are there Western clinical trials of Semax?
No substantial Western clinical programme exists, and no Western regulator has reviewed it.
Which paper is the best starting point?
The 2006 Brain Research study on BDNF and trkB expression, PMID 16996037, is the most cited mechanistic entry point.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSemax regulates BDNF and trkB expression. Brain Res 2006 (PMID 16996037)pubmed.ncbi.nlm.nih.gov
- PubMedSemax in focal ischaemia. BMC Genomics 2014 (PMID 24661604)pubmed.ncbi.nlm.nih.gov
- PubMedEfficacy of semax at stages of ischaemic stroke. 2018 (PMID 29798983)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Semax (ACTH Fragment Peptide) articles
- Semax Regulatory Status: Registered Where, and Why It MattersSemax is a registered medicine in the Russian Federation and holds no MHRA, EMA or FDA authorisation. What a national registration does and does not mean.
- Semax CAS Number and Chemical IdentitySemax CAS Registry Number is 80714-61-0, PubChem CID 9811102, UNII I5FAL2585H. Identifiers for checking a certificate against the literature.
- Semax Storage, Stability and ReconstitutionSemax is proline-stabilised and lacks cysteine, so handling is simpler than most - but its single methionine oxidises. Storage and reconstitution.
- Semax vs Selank: How They DifferSemax derives from ACTH, Selank from tuftsin. Both use a Pro-Gly-Pro extension and both came from the same institute, but their parent peptides differ entirely.
- Where ACTH, Alpha-MSH and Beta-Endorphin All Come FromProopiomelanocortin is cleaved into different products in different tissues. The peptides it yields underlie three separate product categories here.